54 related articles for article (PubMed ID: 30521130)
1. The association between markers of tumour cell metabolism, the tumour microenvironment and outcomes in patients with colorectal cancer.
Roseweir AK; Clark J; McSorley ST; vanWyk HC; Quinn JA; Horgan PG; McMillan DC; Park JH; Edwards J
Int J Cancer; 2019 May; 144(9):2320-2329. PubMed ID: 30521130
[TBL] [Abstract][Full Text] [Related]
2. The relationship between tumour stroma percentage, the tumour microenvironment and survival in patients with primary operable colorectal cancer.
Park JH; Richards CH; McMillan DC; Horgan PG; Roxburgh CSD
Ann Oncol; 2014 Mar; 25(3):644-651. PubMed ID: 24458470
[TBL] [Abstract][Full Text] [Related]
3. Histopathological tumour microenvironment score independently predicts outcome in primary operable colorectal cancer.
Hatthakarnkul P; Pennel K; Alexander P; van Wyk H; Roseweir A; Inthagard J; Hay J; Andersen D; Maka N; Park J; Roxburgh C; Thuwajit C; McMillan D; Edwards J
J Pathol Clin Res; 2024 May; 10(3):e12374. PubMed ID: 38650367
[TBL] [Abstract][Full Text] [Related]
4. The Chemokine CXCL7 is Correlated with LDH-A and Predicts the Prognosis of Patients with Colorectal Cancer.
Liang H; Li L; Huang B; Cheng G; Ao J; Hao S
Front Biosci (Landmark Ed); 2024 Apr; 29(4):166. PubMed ID: 38682188
[TBL] [Abstract][Full Text] [Related]
5. Importance of glycolysis and oxidative phosphorylation in advanced melanoma.
Ho J; de Moura MB; Lin Y; Vincent G; Thorne S; Duncan LM; Hui-Min L; Kirkwood JM; Becker D; Van Houten B; Moschos SJ
Mol Cancer; 2012 Oct; 11():76. PubMed ID: 23043612
[TBL] [Abstract][Full Text] [Related]
6. Back to the future: routine morphological assessment of the tumour microenvironment is prognostic in stage II/III colon cancer in a large population-based study.
Hynes SO; Coleman HG; Kelly PJ; Irwin S; O'Neill RF; Gray RT; McGready C; Dunne PD; McQuaid S; James JA; Salto-Tellez M; Loughrey MB
Histopathology; 2017 Jul; 71(1):12-26. PubMed ID: 28165633
[TBL] [Abstract][Full Text] [Related]
7. The Glasgow Microenvironment Score and risk and site of recurrence in TNM I-III colorectal cancer.
Alexander PG; van Wyk HC; Pennel KAF; Hay J; McMillan DC; Horgan PG; Roxburgh CSD; Edwards J; Park JH
Br J Cancer; 2023 Feb; 128(4):556-567. PubMed ID: 36476660
[TBL] [Abstract][Full Text] [Related]
8. Heterocyclic and non-heterocyclic arena of monocarboxylate transporter inhibitors to battle tumorigenesis.
Manisha DS; Ratheesh AK; Benny S; Presanna AT
Chem Biol Drug Des; 2023 Dec; 102(6):1604-1617. PubMed ID: 37688395
[TBL] [Abstract][Full Text] [Related]
9. Immunological and prognostic significance of tumour necrosis in colorectal cancer.
Kastinen M; Sirniö P; Elomaa H; Ahtiainen M; Väyrynen SA; Herzig KH; Meriläinen S; Aro R; Häivälä R; Rautio T; Saarnio J; Wirta EV; Helminen O; Seppälä TT; Kuopio T; Böhm J; Tuomisto A; Mecklin JP; Mäkinen MJ; Väyrynen JP
Br J Cancer; 2023 Jun; 128(12):2218-2226. PubMed ID: 37031328
[TBL] [Abstract][Full Text] [Related]
10. Evaluating Prognostic Value of Dynamics of Circulating Lactate Dehydrogenase in Colorectal Cancer Using Modeling and Machine Learning.
Ding H; Yuan M; Yang Y; Gupta M; Xu XS
Clin Pharmacol Ther; 2024 Apr; 115(4):805-814. PubMed ID: 37724436
[TBL] [Abstract][Full Text] [Related]
11. PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer.
Yaghoubi N; Soltani A; Ghazvini K; Hassanian SM; Hashemy SI
Biomed Pharmacother; 2019 Feb; 110():312-318. PubMed ID: 30522017
[TBL] [Abstract][Full Text] [Related]
12. Roles of CD133 in microvesicle formation and oncoprotein trafficking in colon cancer.
Kang M; Kim S; Ko J
FASEB J; 2019 Mar; 33(3):4248-4260. PubMed ID: 30521383
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of Monocarboxylate Transporter 1 Overexpression in Cancer: A Systematic Review.
Silva A; Cerqueira MC; Rosa B; Sobral C; Pinto-Ribeiro F; Costa MF; Baltazar F; Afonso J
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982217
[TBL] [Abstract][Full Text] [Related]
14. Relationship between Tumor Budding and Partial Epithelial-Mesenchymal Transition in Head and Neck Cancer.
Okuyama K; Suzuki K; Yanamoto S
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831453
[TBL] [Abstract][Full Text] [Related]
15. HIF: a master regulator of nutrient availability and metabolic cross-talk in the tumor microenvironment.
Missiaen R; Lesner NP; Simon MC
EMBO J; 2023 Mar; 42(6):e112067. PubMed ID: 36808622
[TBL] [Abstract][Full Text] [Related]
16. Lactate: A regulator of immune microenvironment and a clinical prognosis indicator in colorectal cancer.
Zhu D; Jiang Y; Cao H; Yang J; Shu Y; Feng H; Yang X; Sun X; Shao M
Front Immunol; 2022; 13():876195. PubMed ID: 36091047
[TBL] [Abstract][Full Text] [Related]
17. Lactate shuttle: from substance exchange to regulatory mechanism.
Wang X; Liu H; Ni Y; Shen P; Han X
Hum Cell; 2022 Jan; 35(1):1-14. PubMed ID: 34606041
[TBL] [Abstract][Full Text] [Related]
18. Prognostic Nomogram for Patients with Radical Surgery for Non-Metastatic Colorectal Cancer Incorporating Hematological Biomarkers and Clinical Characteristics.
Long P; Zang Y; Wang H; Liang X; Xie X; Han Z; Lin D; Wang Z; Huang S; Chen C
Onco Targets Ther; 2020; 13():2093-2102. PubMed ID: 32210575
[TBL] [Abstract][Full Text] [Related]
19. Intrinsic and Extrinsic Determinants of T Cell Metabolism in Health and Disease.
Munford H; Dimeloe S
Front Mol Biosci; 2019; 6():118. PubMed ID: 31709265
[TBL] [Abstract][Full Text] [Related]
20. The interplay of circulating tumor DNA and chromatin modification, therapeutic resistance, and metastasis.
Zhang L; Liang Y; Li S; Zeng F; Meng Y; Chen Z; Liu S; Tao Y; Yu F
Mol Cancer; 2019 Mar; 18(1):36. PubMed ID: 30849971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
